Fact-checked by Grok 2 weeks ago

Classical complement pathway

The classical complement pathway is one of the three main activation routes of the complement system, a key component of innate immunity that enhances antibody-mediated responses by initiating a proteolytic cascade leading to pathogen opsonization, inflammation, and cytolysis.^[1] It is triggered when the recognition molecule C1q binds to the Fc regions of immunoglobulin M (IgM) or clustered immunoglobulin G (IgG) in antigen-antibody immune complexes on pathogen surfaces, or to non-antibody ligands such as C-reactive protein, apoptotic cells, or certain viral proteins.^[2] This binding induces a conformational change in the C1 complex (comprising C1q, C1r, and C1s), activating the serine protease C1s, which cleaves complement component C4 into C4a and C4b fragments, followed by cleavage of C2 into C2a and C2b to form the C3 convertase enzyme C4b2a on the target surface.^[3] The C3 convertase then cleaves C3 into C3a (an anaphylatoxin promoting inflammation) and C3b (which opsonizes targets for phagocytosis and associates with C4b2a to form the C5 convertase C4b2a3b).^[1] This amplifies the response, culminating in C5 cleavage into C5a (another anaphylatoxin) and C5b, which initiates assembly of the membrane attack complex (C5b-9) to lyse infected cells or pathogens.^[2] Discovered in the late 19th century through studies on bacteriolysis—initially termed "alexin" by Buchner in 1891 and later delineated by Bordet and Ehrlich as involving heat-labile serum factors and antibodies—the pathway's molecular components were progressively identified, with the World Health Organization standardizing nomenclature in 1968.^[2] Unlike the alternative pathway (which spontaneously activates on foreign surfaces) or the lectin pathway (triggered by mannose-binding lectins), the classical pathway uniquely integrates adaptive immunity by relying on humoral antibodies, making it essential for effective clearance of encapsulated bacteria and immune complexes in conditions like systemic lupus erythematosus.^[3] The cascade is tightly regulated to prevent host tissue damage, primarily by C1-inhibitor (which dissociates and inactivates C1r and C1s), factor I (which degrades C3b and C4b with cofactors like factor H or C4b-binding protein), and membrane-bound protectors such as decay-accelerating factor (CD55), membrane cofactor protein (CD46), and protectin (CD59).^[1] Dysregulation of this pathway contributes to autoimmune diseases, hereditary angioedema, and atypical hemolytic uremic syndrome, while therapeutic agents like the C5 inhibitor eculizumab highlight its clinical significance in controlling excessive activation.^[3]

Overview

Definition and activation triggers

The classical complement pathway is an antibody-mediated branch of the complement system, a key component of innate immunity that orchestrates the sequential activation of soluble plasma proteins to facilitate pathogen clearance. This pathway initiates a proteolytic cascade that generates opsonins to tag microbes for phagocytosis, anaphylatoxins to promote inflammation, and the membrane attack complex to lyse target cells.^[4]^[5] Activation of the classical pathway primarily occurs through the binding of the recognition molecule C1q to the Fc regions of immunoglobulin G (IgG) or immunoglobulin M (IgM) antibodies that are complexed with antigens on pathogen surfaces, thereby linking adaptive immunity to innate effector functions. Additionally, C1q can directly recognize and bind to exposed structures on apoptotic or necrotic cells, facilitating their non-inflammatory clearance, and it interacts with acute-phase proteins such as C-reactive protein (CRP), which binds to phosphocholine on damaged cells or microbes to trigger the pathway during inflammation.^[4]^[1]^[6]^[7] The classical pathway was identified in the 1930s and 1940s through pioneering studies on the bactericidal activity of serum, which demonstrated that heat-labile factors in plasma, in conjunction with heat-stable antibodies, were essential for lysing antibody-coated bacteria. Researchers such as Michael Heidelberger advanced this understanding with quantitative immunochemical analyses of complement's role in antigen-antibody reactions, while Manfred M. Mayer's reconstitution experiments in the 1940s using sensitized sheep erythrocytes helped delineate the multi-component nature of the pathway's lytic mechanism.^[2]^[8] The pathway encompasses the core complement proteins C1 through C9, which are present in plasma as inactive precursors and become sequentially activated in a tightly regulated manner to amplify the immune response without detailing specific cleavage events here. C1 serves as the initiating complex, while C3 acts as the central amplifier, and C5–C9 form the terminal lytic components.^[4]^[5]

Role in immune response

The classical complement pathway plays a pivotal role in the innate immune response by facilitating opsonization, inflammation, and direct pathogen elimination. Upon activation, it generates C3b, which covalently binds to pathogen surfaces, marking them for enhanced phagocytosis by macrophages and neutrophils through receptors such as CR1 and CR3.^[9] Additionally, the pathway produces anaphylatoxins C3a and C5a, which promote mast cell degranulation, histamine release, and chemotaxis of eosinophils, basophils, and other immune cells to sites of infection, thereby amplifying local inflammatory responses.^[10] The terminal phase culminates in the assembly of the membrane attack complex (MAC, C5b-9), which inserts into lipid bilayers of Gram-negative bacteria and enveloped viruses, inducing osmotic lysis and pathogen clearance.^[9] This pathway integrates closely with adaptive immunity, enhancing antibody-mediated responses and bridging innate and humoral defenses. By opsonizing antigens with C3b and C3d, it lowers the activation threshold for B cells by up to 10,000-fold via co-ligation of the B-cell receptor with complement receptor 2 (CR2/CD21), thereby boosting germinal center reactions and antibody affinity maturation.^[9] Complement-opsonized antigens captured by follicular dendritic cells further sustain T-dependent B-cell responses, while C3a signaling on dendritic cells promotes Th1 polarization and cytotoxic T-lymphocyte priming, collectively amplifying pathogen clearance.^[10] In comparison to other complement activation routes, the classical pathway is uniquely antibody-dependent, triggered primarily by C1q binding to IgG or IgM immune complexes, in contrast to the lectin pathway's recognition of mannose-binding lectins on microbial carbohydrates or the alternative pathway's spontaneous hydrolysis of C3 coupled with pattern recognition.^[9] Despite these distinct initiation mechanisms, all three pathways converge at the C3 convertase stage, enabling shared downstream amplification and effector functions.^[10] The classical pathway exhibits strong evolutionary conservation, emerging in jawed vertebrates such as cartilaginous and bony fish, where it supports primitive adaptive immunity through antibody-like molecules. Beyond pathogen defense, it contributes to homeostasis by facilitating the non-inflammatory clearance of apoptotic cells and cellular debris via C1q-mediated opsonization, preventing autoimmunity and tissue damage.^[9]

Initiation of the pathway

Binding of C1q

C1q, the recognition subunit of the C1 complex, is a 460-kDa multimeric protein composed of six identical heterotrimeric subunits, each formed by one A, B, and C chain. These subunits assemble into a bouquet-like hexameric structure, featuring N-terminal collagen-like tails that form triple-helical stalks and C-terminal globular heads (gC1q domains) responsible for ligand recognition.^[11] The collagen-like region provides flexibility and multivalency, allowing the globular heads—each a heterotrimer approximately 50 Å in diameter—to interact simultaneously with multiple targets.^[11] Binding of C1q to immune complexes occurs primarily through its six globular heads interacting with the Fc regions of antibodies, with specificity for IgG and IgM. For IgG, effective binding and pathway activation require at least two Fc regions in close proximity (within 10-40 nm), enabling multivalent attachment that increases avidity on surfaces coated with clustered antibodies, such as those on pathogens.^[12] In contrast, pentameric IgM presents multiple Fc sites in a single molecule, facilitating high-affinity binding even without additional clustering.^[11] This antibody-dependent recognition serves as the primary trigger for the classical complement pathway. Upon ligand binding, C1q undergoes a conformational rearrangement, characterized by an outward splaying of its collagen-like stalks, which propagates a signal to the associated C1r proteases. This change exposes previously inaccessible sites on the collagen tails, allowing C1r dimerization and subsequent activation within the C1 complex.^[12]^[13] In addition to antibody-mediated initiation, C1q can recognize non-antibody ligands on damaged or altered cells, contributing to innate immune surveillance. It binds exposed lipids such as phosphatidylserine on apoptotic cell surfaces and certain carbohydrates, including those derived from DNA like deoxy-D-ribose, on necrotic or infected cells.^[11] These interactions enable direct activation of the classical pathway in the absence of antibodies.^[11]

Activation of C1r and C1s

The C1 complex in the classical complement pathway is composed of one C1q molecule that recruits two C1r and two C1s zymogen molecules, forming a Ca²⁺-dependent tetrameric protease (C1r₂C1s₂) associated with the collagen-like stalks of C1q.^[4] This assembly positions the serine protease domains of C1r and C1s peripherally, enabling their activation upon surface binding.^[14] The stoichiometry of 1:2:2 (C1q:C1r:C1s) ensures coordinated proteolytic potential within each C1 complex.^[15] Activation begins when C1q binding to an immune complex or pathogen surface induces a conformational change in the C1 complex, promoting dimerization of the C1r zymogens through their CUB1-EGF interaction domains.^[14] This leads to intermolecular autocleavage of C1r by a neighboring C1 complex, converting C1r into its active serine protease form, as the protease domains are spatially separated (approximately 39 nm apart) within a single complex.^[14] Typically, one C1 complex associates per immune complex via C1q recognition, setting the stage for downstream amplification.^[4] Activated C1r then performs limited proteolysis on C1s, cleaving it at specific arginine-isoleucine bonds to generate active C1s, also through likely intercomplex interactions given the 28 nm separation of C1s protease domains.^[14] C1s functions as the primary serine protease effector in the complex, poised to initiate subsequent cleavages, though its activity is rapidly controlled by the serpin C1-inhibitor (C1-INH).^[4]

Formation of the C3 convertase

Cleavage of C4 and C2

Activated C1s, the serine protease within the C1 complex, initiates the next phase by cleaving the complement component C4. C4 is a 200 kDa glycoprotein synthesized as a single-chain precursor that is processed into three chains (α, β, γ) linked by disulfide bonds. Upon cleavage by C1s at a specific arginine-leucine bond in the α-chain, C4 generates the small fragment C4a (~9 kDa) and the larger C4b (~190 kDa).^[16]^[17] The C4b fragment contains an internal thioester bond buried within the α-chain, which becomes reactive immediately after cleavage. This thioester, formed between a glutamine residue and a cysteine, undergoes hydrolysis or transacylation, allowing C4b to covalently attach to nearby nucleophiles such as free amines on proteins or hydroxyl groups on carbohydrates within microseconds. The reaction favors surface-bound targets, with C4A allotypes preferring amide linkages to amines and C4B allotypes favoring ester linkages to carbohydrates, thereby anchoring C4b efficiently to pathogen surfaces or immune complexes.^[18]^[19] C4a functions as an anaphylatoxin, binding to G-protein-coupled receptors on mast cells, basophils, and other immune cells to induce degranulation, histamine release, and vasodilation, thereby promoting local inflammation and enhancing immune recruitment. In contrast, C4b serves as a stable surface anchor, providing a platform for subsequent interactions while its rapid deposition kinetics—occurring at rates at least an order of magnitude faster than thioester hydrolysis—minimize fluid-phase inactivation.^[20]^[16] Following C4 cleavage, C2 is recruited and cleaved by C1s in a magnesium ion (Mg²⁺)-dependent manner. C2, a 102 kDa single-chain proenzyme, binds to the C4b fragment via its C-terminal region, requiring Mg²⁺ to stabilize the interaction. C1s then cleaves C2 at an arginine-lysine bond, producing C2a (~70 kDa), the catalytic serine protease domain, and C2b (~34 kDa), the non-enzymatic regulatory fragment.^[21] The kinetics of C2 cleavage are tightly coupled to prior C4b deposition, with C2 recruitment occurring rapidly after surface activation to favor localized amplification. This surface-restricted process is far more efficient than in the fluid phase, where spontaneous hydrolysis and inhibitor competition limit convertase formation, ensuring targeted immune response without systemic dissemination.^[17]^[16]

Assembly of C4b2a complex

The assembly of the C4b2a complex, the classical pathway's C3 convertase, initiates with the covalent attachment of C4b to the target surface via its reactive thioester bond, which is exposed following cleavage of C4 by activated C1s.^[3] This surface-bound C4b serves as a platform for the subsequent binding of C2 in a magnesium ion (Mg²⁺)-dependent manner, where C2 associates with C4b to position itself for proteolysis.^[3] C1s then cleaves C2 into the fragments C2a and C2b; the C2a subunit remains non-covalently bound to C4b through a Mg²⁺-mediated bridge, forming the stable yet transient C4b2a enzyme.^[22] The cleavage products C4b and C2a thus integrate to generate this key proteolytic complex.^[23] Anchored to the target membrane or immune complex via the thioester linkage of C4b, the C4b2a complex ensures spatially restricted activation, directing complement amplification toward the initiating site such as a pathogen surface.^[3] Enzymatically, C4b2a functions as a serine protease that specifically cleaves the substrate C3 at the Arg-Ser bond within its alpha chain, enabling downstream cascade progression.^[22] On surfaces, the complex maintains activity for approximately 10 minutes before inactivation, a duration dictated by its inherent instability.^[3] Inactivation occurs primarily through the spontaneous release of the C2a subunit, which dissociates from C4b and renders the complex enzymatically inactive.^[22] This decay process is further accelerated by host regulatory proteins, including decay-accelerating factor (DAF) and complement receptor 1 (CR1), which promote C2a dissociation to prevent unwarranted complement activation on host cells.^[3]

Amplification phase

C3 cleavage and opsonization

Complement component C3 is a multidomain glycoprotein of approximately 185 kDa, structurally similar to C4 as both belong to the thioester-containing protein (TEP) superfamily, featuring homologous domains such as macroglobulin (MG) domains and a thioester domain (TED).^[24] It consists of an α-chain (about 110 kDa) and a β-chain (about 75 kDa) linked by a disulfide bridge, with the reactive thioester bond located within the TED of the α-chain between Cys-988 and Gln-991 residues.^[24] This thioester remains shielded in the native form but becomes exposed upon activation, enabling covalent attachment to target surfaces.^[24] In the classical pathway, the C4b2a complex serves as the C3 convertase, cleaving C3 at the Arg77-Ser78 bond within the α-chain to generate the anaphylatoxin C3a and the larger fragment C3b.^[25] C3a, a 77-residue peptide, functions as a potent anaphylatoxin that binds to the C3a receptor (C3aR) on mast cells, inducing degranulation and release of histamine and other mediators to promote inflammation.^[26] The resulting C3b fragment undergoes a conformational change that exposes the thioester, allowing it to act as a primary opsonin by covalently binding to pathogen surfaces or immune complexes.^[24] Cleavage efficiency is notably higher when the convertase is surface-bound compared to fluid-phase forms, as surface immobilization concentrates substrates and reduces diffusion losses, enhancing local activation. Opsonization by C3b facilitates recognition and uptake by phagocytes through interactions with complement receptors. Deposited C3b is subject to limited proteolysis by factor I in the presence of cofactors such as CR1 (CD35), yielding iC3b, which exposes additional binding sites for CR3 (CD11b/CD18) and CR4 (CD11c/CD18) on macrophages and neutrophils.^[27] Further factor I-mediated cleavage of iC3b produces C3dg, a fragment that binds primarily to CR2 (CD21) on B cells to facilitate antigen-specific activation and immune complex retention, with limited opsonizing potential via CR1 for phagocytic attachment.^[27]^[28] This stepwise degradation modulates the opsonin's affinity, ensuring progressive immune clearance while preventing excessive activation.^[27] The cleavage of C3 initiates an amplification phase where each generated C3b molecule can associate with factor B to form additional C3 convertases via the alternative pathway, recruiting more C2 and C4 components in the classical context to exponentially increase C3b deposition on targets.^[29] This feedback loop provides substantial amplification potential, with a single initial convertase potentially yielding hundreds of C3b molecules, thereby scaling the immune response proportionally to the threat.^[29] Such exponential deposition underscores C3's central role in bridging pathway initiation to robust effector functions.^[29]

Deposition of C3b

Following cleavage of C3 by the C4b2a convertase, the nascent C3b fragment exposes a highly reactive thioester bond within its alpha chain, enabling covalent attachment to nearby nucleophilic groups on target surfaces.^[30] This thioester reacts preferentially with hydroxyl groups on carbohydrates or amino groups on proteins, forming stable ester or amide linkages that anchor C3b directly to pathogen membranes or immune complexes.^[31] The process is highly efficient due to the short-lived nature of the thioester (half-life of about 60 microseconds), which confines deposition to immediate proximity of the activation site, ensuring targeted opsonization.^[4] The initial deposition of C3b creates a positive feedback mechanism that rapidly increases surface density through amplification. Deposited C3b molecules serve as nucleation sites, recruiting additional complement components to form more C3 convertase complexes, thereby cleaving further C3 and perpetuating thioester-mediated attachments.^[32] In the classical pathway context, this amplification loop—often bolstered by alternative pathway elements—can deposit up to 10^5 C3b molecules per target cell within seconds, dramatically enhancing immune recognition and effector functions.^[33] Once deposited, C3b undergoes regulated processing to iC3b via limited proteolysis by factor I in concert with cofactor proteins such as membrane cofactor protein (MCP) or complement receptor 1 (CR1).^[34] This conversion exposes new ligand sites on iC3b while retaining the ability to bind complement receptor 2 (CR2, also known as CD21) on B cells, facilitating antigen-specific B-cell activation and antibody responses by lowering the threshold for B-cell receptor signaling.^[35] The multimeric arrays of C3b and iC3b thus not only amplify opsonization but also bridge innate and adaptive immunity through these receptor interactions.^[36]

Terminal pathway

Formation of C5 convertase

The formation of the C5 convertase in the classical complement pathway occurs through the covalent attachment of a C3b molecule to the preexisting C3 convertase complex, C4b2a, resulting in the trimolecular enzyme C4b2a3b. This assembly enhances the enzyme's substrate specificity, shifting its primary activity from C3 cleavage to that of C5, thereby transitioning the pathway toward its terminal phase.^[2] The binding mechanism involves the thioester domain (TED) of C3b, which exposes a reactive thioester group upon C3 activation; this group forms a covalent ester linkage with a specific hydroxyl group on the TED of C4b, typically at serine or threonine residues. This interaction ensures that the C3b component remains surface-bound near the original C4b deposition site, maintaining spatial proximity to the target membrane and optimizing the lytic potential of downstream events. The ester bond itself exhibits moderate stability, with a half-life of approximately 8 hours at physiological conditions, though the overall C4b2a3b complex is more labile.^[37]48053-6/fulltext) Once formed, the C5 convertase C4b2a3b exhibits approximately a 100-fold greater efficiency in cleaving C5 compared to C3, reflecting the allosteric influence of the bound C3b on the catalytic site provided by C2a. It specifically hydrolyzes the peptide bond between arginine and leucine residues (Arg751-Leu752) in the alpha chain of C5, generating the anaphylatoxin fragment C5a—a potent mediator of inflammation, chemotaxis, and vascular permeability—and the larger C5b fragment that nucleates subsequent assembly steps. The enzyme's activity is transient, with a functional half-life of about 5 minutes at 37°C, necessitating rapid progression to sustain pathway amplification.^[38]^[39]83153-6/fulltext)

Assembly of the membrane attack complex (MAC)

The assembly of the membrane attack complex (MAC), also known as C5b-9, begins following the generation of C5b through cleavage in the terminal pathway. C5b rapidly binds to C6, forming the stable C5b-6 complex, which then associates with C7 to create the C5b-7 complex. This C5b-7 entity exposes hydrophobic regions that facilitate its insertion into the lipid bilayer of the target cell membrane, anchoring the nascent complex and initiating pore formation.^[40]^[41] Subsequent binding of C8 to the membrane-inserted C5b-7 forms the C5b-8 complex, which further penetrates the bilayer via the hydrophobic domain of the C8α subunit. C8 then nucleates the polymerization of multiple C9 monomers, typically 12-18 molecules, into a ring-like structure. These C9 units assemble into a β-barrel pore with an internal diameter of approximately 100 Å (10 nm), creating a transmembrane channel that spans the membrane. The resulting C5b-9 MAC forms irregular, arc-shaped or complete cylindrical pores, with the flexible β-hairpins of C9 facilitating membrane disruption.^[40]^[41]^[42] The primary lytic mechanism of the MAC involves the pore allowing uncontrolled influx of water and ions, leading to colloid osmotic lysis and target cell death, particularly effective against enveloped pathogens and certain nucleated cells. At sublytic concentrations, MAC induces signaling pathways such as PI3K/Akt and ERK1/2 activation, promoting proinflammatory cytokine release and cell survival signals that amplify inflammation without causing lysis.^[40]^[41]^[42] In non-lytic contexts, soluble forms of the MAC (sC5b-9) arise when vitronectin (S-protein) binds to fluid-phase C5b-7, preventing membrane insertion and polymerization. This sC5b-9 complex serves as a circulating biomarker for complement activation in inflammatory diseases, such as systemic lupus erythematosus, and exhibits opsonin-like functions by enhancing immune cell activation and proinflammatory responses through endothelial signaling.^[40]^[42]

Regulation

Soluble and membrane-bound inhibitors

The classical complement pathway is tightly regulated by a suite of soluble and membrane-bound inhibitors that prevent uncontrolled activation and amplification on host cells. These regulators act at multiple stages, including the inhibition of early proteases, decay of convertase complexes, and inactivation of deposited components, ensuring that complement activity is directed primarily toward pathogens.^[2]^[43] Soluble inhibitors play a critical role in controlling the fluid-phase activation of the classical pathway. C1 esterase inhibitor (C1-INH), a serine protease inhibitor synthesized primarily in the liver, irreversibly binds to and inactivates the activated C1r and C1s serine proteases, thereby preventing the initiation of the cascade; under physiological conditions, this limits the half-life of activated C1 to approximately 13 seconds.^[2]^[43] C4-binding protein (C4BP), another liver-derived soluble regulator, binds to C4b and serves as a cofactor for factor I-mediated cleavage of C4b into inactive fragments, while also accelerating the decay of the classical C3 convertase (C4b2a).^[2]^[44] Factor I, a soluble serine protease circulating in plasma, proteolytically inactivates C3b and C4b by cleaving them into iC3b and C4c/C4d fragments, respectively, but requires cofactors such as C4BP for efficient action on classical pathway components.^[43]^[44] Factor H, while primarily regulating the alternative pathway through competitive binding to C3b and acceleration of its convertase decay, has a limited ancillary role in the classical pathway by supporting factor I in C3b inactivation.^[2]^[44] Additionally, vitronectin, a soluble plasma glycoprotein, binds to the C5b-7 complex in the terminal pathway initiated by classical activation, preventing its insertion into membranes through competitive binding and forming a soluble SC5b-9 complex that inhibits further polymerization of C9.^[44]^[43] Membrane-bound inhibitors provide localized protection on host cells by targeting convertase complexes and deposited complement fragments. Decay-accelerating factor (DAF, or CD55), a glycosylphosphatidylinositol (GPI)-anchored protein expressed on most blood cells, accelerates the dissociation of the classical C3 convertase (C4b2a) and C5 convertase by binding to C4b and C2a, thereby limiting amplification on cell surfaces.^[2]^[43] Membrane cofactor protein (MCP, or CD46), a transmembrane glycoprotein ubiquitously expressed on nucleated cells, acts as a cofactor for factor I, facilitating the proteolytic cleavage of C3b to iC3b and C4b to C4d, which disrupts convertase assembly in the classical pathway.^[44]^[43] Complement receptor 1 (CR1, or CD35), found on erythrocytes, leukocytes, and other cells, similarly functions as both a decay-accelerating factor for C3 and C5 convertases and a cofactor for factor I-mediated inactivation of C3b and C4b, enhancing the protective threshold on host membranes.^[2]^[44] Protectin (CD59), a GPI-anchored protein expressed on many cell types, inhibits the terminal pathway by binding to C5b-8 and preventing the polymerization of C9, thereby blocking the formation of the membrane attack complex on host cells.^[2] These inhibitors employ distinct mechanisms to curtail classical pathway activity, with proteolytic inactivation being central to soluble regulators like factor I, which sequentially cleaves alpha chains of C3b and C4b in the presence of cofactors, rendering them unable to sustain convertase function.^[43] Competitive binding mechanisms, such as those used by vitronectin to sequester C5b-7 or by DAF to displace convertase subunits, further prevent membrane perturbation without direct proteolysis.^[44] The classical pathway exhibits pathway-specific reliance on early inhibitors like C1-INH and C4BP to block initiation at the C1 complex and C4b level, in contrast to the alternative pathway's greater dependence on factor H for C3b opsonin control.^[2]^[44]

Importance in preventing host damage

The classical complement pathway's potent inflammatory and lytic capabilities necessitate stringent regulation to avert inadvertent damage to host tissues, as uncontrolled activation can lead to the deposition of complement components on healthy cells, triggering inflammation and tissue injury, particularly in endothelial cells.^[45] Without such oversight, the pathway's amplification could promote autoimmunity by fostering chronic immune responses against self-antigens, resulting in persistent host cell lysis and exacerbated inflammatory cascades.^[44] In homeostatic contexts, regulated complement activity facilitates the non-inflammatory clearance of apoptotic cells and immune complexes, thereby preserving immune tolerance and preventing the accumulation of potentially immunogenic debris that might otherwise incite autoimmune reactions.^[46] This controlled process ensures that opsonization and phagocytosis occur efficiently on modified self-surfaces without eliciting damaging inflammation, supporting tissue homeostasis and organ integrity.^[47] From an evolutionary standpoint, the complement system's inhibitors have evolved to maintain a delicate balance, restricting amplification to pathogen-associated surfaces and averting systemic dissemination that could compromise host viability. This target-specific restraint allows the pathway to mount robust defenses while safeguarding bystander cells, reflecting an adaptive strategy honed over millennia to optimize innate immunity without self-harm.^[48] Quantitative mechanisms further enforce this precision, such as the requirement for at least two adjacent IgG molecules to engage C1q for pathway initiation, establishing a density-dependent activation threshold that minimizes spurious triggering on sparse host-bound antibodies.^[49] Additionally, the inherent instability of convertases, like the classical C3 convertase (C4b2a) with its relatively short half-life, coupled with rapid decay acceleration by regulators, ensures transient activation confined to high-avidity targets.^[3]

Clinical significance

Associated diseases

Deficiencies in components of the classical complement pathway are strongly associated with immune dysregulation and increased disease susceptibility. Homozygous C1q deficiency, a rare genetic disorder, leads to early-onset systemic lupus erythematosus (SLE)-like autoimmunity, characterized by recurrent bacterial infections and a high risk of developing lupus nephritis or other autoimmune manifestations.^[50] Similarly, deficiencies in other early classical pathway components, such as C1r, C1s, C2, and C4, predispose individuals to SLE or SLE-like syndromes, with C4 deficiency particularly linked to immune complex-mediated glomerulonephritis.^[51] C1 esterase inhibitor (C1-INH) deficiency, while primarily causing hereditary angioedema through uncontrolled bradykinin production, also results in chronic complement activation and consumption of C4, contributing to vascular permeability and episodic swelling attacks.^[52] Autoimmune diseases are further exacerbated by autoantibodies targeting classical pathway initiators. Anti-C1q antibodies are prevalent in SLE patients, particularly those with active lupus nephritis, where they correlate with disease activity and promote complement-mediated glomerular damage by enhancing C1q deposition on immune complexes.^[53] These antibodies are found in up to 30-40% of SLE cases and serve as a biomarker for renal involvement, independent of overall complement levels.^[54] Impairment of the classical pathway heightens vulnerability to infections, especially from encapsulated bacteria. Individuals with deficiencies in C1, C2, or C4 exhibit recurrent infections with pathogens like Streptococcus pneumoniae and Haemophilus influenzae due to defective opsonization and phagocytosis of these microbes.^[55] This susceptibility arises from insufficient C3b deposition triggered via the classical route, underscoring the pathway's role in humoral immunity against such organisms.^[56] Recent research has implicated classical pathway dysregulation in neurodegenerative and inflammatory conditions. In COVID-19, persistent activation of the classical pathway, driven by C1q binding to viral-antibody complexes, contributes to hyperinflammation and endothelial damage in severe cases, with elevated C3a and C5a levels correlating with worse outcomes.^[57] In Alzheimer's disease, C1q facilitates excessive microglial pruning of synapses in the aging brain, promoting neurodegeneration; studies in mouse models show that C1q knockout reduces synaptic loss and amyloid-beta plaque-associated inflammation.^[58]

Therapeutic interventions

Therapeutic interventions targeting the classical complement pathway primarily focus on replacing deficient components or inhibiting overactive elements to manage conditions like hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency. Plasma-derived C1-INH concentrates, such as Berinert, are approved for acute treatment and prophylaxis of HAE attacks by restoring functional C1-INH levels, which inhibits the classical pathway initiation and prevents excessive bradykinin production leading to edema.^[59] These concentrates have demonstrated rapid symptom relief, with intravenous administration reducing attack severity in clinical studies, and a strong safety profile with no confirmed viral transmissions after nanofiltration.^[60] Eculizumab, a monoclonal antibody targeting C5, indirectly modulates the classical pathway by blocking downstream terminal complement activation, which is shared across pathways; it is approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, where classical pathway dysregulation contributes to hemolysis.^[61] By preventing C5 cleavage into C5a and C5b, eculizumab reduces membrane attack complex (MAC) formation, though it does not directly inhibit early classical components like C1q or C4.^[62] Diagnostics for classical pathway dysfunction include the CH50 assay, which measures total hemolytic activity by assessing the pathway's ability to lyse antibody-coated sheep red blood cells, serving as a sensitive screen for deficiencies in C1 through C9 components.^[63] Low CH50 levels indicate classical pathway impairment, guiding further evaluation in suspected immunodeficiencies. The soluble C5b-9 (sC5b-9) complex serves as a biomarker for terminal pathway activation, including from the classical route, with elevated plasma levels correlating to ongoing complement-mediated tissue damage in inflammatory conditions.^[64] Quantification of sC5b-9 via enzyme immunoassay helps monitor therapeutic responses and disease activity.^[65] Emerging therapies emphasize pathway-specific inhibitors to minimize broad immunosuppression while addressing classical pathway hyperactivation. Sutimlimab, a humanized monoclonal antibody against C1s, selectively inhibits the classical pathway by preventing C4 cleavage and downstream amplification, showing sustained efficacy in cold agglutinin disease with improved hemoglobin levels and reduced hemolysis over 144 weeks.^[66] This approach avoids interfering with alternative or lectin pathways, potentially reducing infection risks associated with pan-complement blockade. For systemic lupus erythematosus (SLE), where classical pathway activation via immune complexes exacerbates nephritis, investigational anti-C1q strategies, including anti-idiotypic antibodies targeting pathogenic anti-C1q autoantibodies, have demonstrated preclinical reduction in lupus symptoms in murine models.^[67] Gene therapies for C1-INH deficiency in HAE include AAV-based vectors such as BMN 331 (AAV5-hSERPING1) delivering functional SERPING1, which has advanced to phase 1/2 clinical trials as of 2025, showing potential for long-term C1-INH expression and attack prevention.^[68] CRISPR-Cas9 editing approaches, such as NTLA-2002 targeting the KLKB1 gene to reduce kallikrein (a downstream effector in HAE), have shown promising phase 1/2 results with single-dose administration reducing angioedema attacks by more than 70% and sustaining kallikrein reduction for up to three years as of 2025; phase 3 trials (HAELO) are ongoing, with enrollment completion anticipated in Q3 2025.^[69]^[70]^[71] In 2025, additional approvals for HAE management include garadacimab (anti-FXIIa monoclonal antibody), donidalorsen (antisense oligonucleotide inhibiting prekallikrein), and sebetralstat (oral kallikrein inhibitor), which target the bradykinin pathway dysregulated in C1-INH deficiency, complementing classical pathway interventions.^[72] In cancer immunotherapy, complement-targeted strategies enhance MAC deposition on tumor cells, with monoclonal antibodies promoting classical pathway activation to boost antibody-dependent cytotoxicity without systemic overactivation.^[73] Recent advances as of 2025 include next-generation inhibitors like bispecific antibodies for refined classical pathway modulation.^[74]

References

[1]
COMPLEMENT: AN OVERVIEW FOR THE CLINICIAN - PMC
The classical pathway is initiated by the binding of the C1 complex (C1q, C1r and C1s) to bound antibody. C1r activates C1s which first cleaves C4 and then ...
[2]
The complement system: history, pathways, cascade and inhibitors
The classical pathway can also be activated by other danger signals like C-reactive protein, viral proteins, polyanions, apoptotic cells and amyloid, thus ...
[3]
Complement System Part I – Molecular Mechanisms of Activation ...
This article will review the mechanisms of activation of alternative, classical, and lectin pathways, the formation of C3 and C5 convertases, the action of ...
[4]
The complement system and innate immunity - Immunobiology - NCBI
The classical pathway can be initiated by the binding of C1q, the first protein in the complement cascade, directly to the pathogen surface. It can also be ...
[5]
Classical Complement Pathway - an overview | ScienceDirect Topics
The classical complement pathway is defined as the antibody-dependent arm of the complement cascade, which is a part of the innate immune system responsible ...
[6]
Complement activation by necrotic cells in normal plasma ...
Aug 5, 2004 · Activation of the classical complement pathway by apoptotic cells occurs via multiple mechanisms including direct interaction of C1q with ...2 Results · 4 Materials And Methods · 4.7 Binding Of Igm, Crp, Sap...<|control11|><|separator|>
[7]
C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from ...
CRP Enhances and Sustains Early Classical Pathway Activation but Attenuates MAC Formation on Apoptotic Cells. CRP has previously been shown to activate ...Missing: triggers | Show results with:triggers
[8]
Antigens and Antibodies: Heidelberger and The Rise of Quantitative ...
Michael Heidelberger's studies of the immunochemistry of antibodies, antigen, and complement redefined the field of immunology and founded it on the precise ...Missing: classical | Show results with:classical
[9]
https://doi.org/10.3389/fimmu.2015.00257
[10]
https://doi.org/10.15252/embj.201591881
[11]
Frontiers | The Human C1q Globular Domain: Structure and Recognition of Non-Immune Self Ligands
### Summary of C1q Structure and Function from the Article
[12]
Deciphering the Fine Details of C1 Assembly and ... - Frontiers
It has long been described in text books that C1 activation involves binding to at least two IgG molecules, each one bound to the surface through its two Fab ...
[13]
Structural basis of the C1q/C1s interaction and its central ... - PNAS
C1q has a bouquet-like structure assembled from six collagenous stems, each with a C-terminal globular head. Binding to pathogens induces a conformational ...<|control11|><|separator|>
[14]
Structure and activation of C1, the complex initiating the ... - PNAS
Jan 19, 2017 · The classical pathway of complement is activated upon binding of the 774-kDa C1 complex, consisting of the recognition molecule C1q and the ...
[15]
Early Components of the Complement Classical Activation Pathway ...
This pathway of complement activation is initiated by the binding of pattern recognition molecules including mannan-binding lectin (MBL) or ficolins to a ...
[16]
Paths reunited: initiation of the classical and lectin pathways of ...
Principally, the C1q binding site on the C1rs tetramer was proposed to lie at the C1r-C1s interface (Gaboriaud et al., 2004), whilst the MBL binding site was ...Introduction · Assembly Of C1 · Activation Of C1s By C1r
[17]
https://doi.org/10.1074/jbc.M401318200
[18]
The internal thioester and the covalent binding properties of ... - NIH
The covalent binding of complement components C3 and C4 is critical for their activities. This reaction is made possible by the presence of an internal ...
[19]
https://doi.org/10.1002/pro.5560060201
[20]
C4a: the third anaphylatoxin of the human complement system. | PNAS
C4a constitutes a heretofore unrecognized anaphylatoxin that is related biologically and chemically to the activation peptides of C3 and C5.
[21]
Effect of sodium chloride concentration on fluid-phase assembly and ...
Nov 1, 1990 · The assembly of the classical-pathway C3 convertase from C4 and I2-treated C2 by the action of C1s is an Mg2(+)-dependent reaction. The Mg2+
[22]
C3‐dependent effector functions of complement - Wiley Online Library
Oct 22, 2022 · Cleavage of C3 at an Arg-Ser bond releases the C3a anaphylatoxin in the fluid phase and triggers a dramatic conformational change in the nascent ...
[23]
Complement activation, regulation, and molecular basis for ...
Complement is activated through the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP). The recognition of invading ...
[24]
Complement component C3 - The “Swiss Army Knife” of innate ...
Complement components C3, C4, and C5 belong to the thioester-containing protein (TEP) superfamily that also includes α2-macroglobulin (α2M), the pregnancy zone ...
[25]
Complement C3 - Homo sapiens (Human) | UniProtKB | UniProt
During activation of the complement systems, the alpha chain is cleaved into C3a and C3b by the C3 convertase: C3b stays linked to the beta chain, while C3a is ...
[26]
https://www.jacionline.org/article/S0091-6749(12)00784-1/fulltext
[27]
Complement Receptors and Their Role in Leukocyte Recruitment ...
Feb 10, 2021 · CR1 is primarily involved in the attachment of C3b-opsonized particles to the cell as shown by the impaired attachment of C3b-coated ...
[28]
Human C3 mutation reveals a mechanism of dense deposit disease ...
Sep 13, 2010 · Convertase-generated C3b can form more AP C3-convertase, providing exponential amplification to the initial activation. Binding of C3b to ...
[29]
Specificity of the thioester-containing reactive site of human C3 ... - NIH
We have examined the thioester in C3 and found evidence of strong preferences for certain carbohydrates, indications of selectivity for specific positions on ...
[30]
A Revised Mechanism for the Activation of Complement C3 to C3b
C3 belongs to the α2-macroglobulin protein family, members of which have a reactive thioester bond and similar domain arrangements (4). The α- and β-chains of ...
[31]
Assembly and regulation of the complement amplification loop in ...
Complement activation via the classical or the lectin pathway activates the amplification loop, whereby the number of deposited C3b molecules greatly ...
[32]
(PDF) An anti-C3b(i) mAB enhances complement activation, C3b(i ...
Aug 6, 2025 · Radioimmunoassay (RIA) demonstrates that about 500 000 C3b(i) molecules deposit ... Deposition of nascent C3b on cell surfaces during complement ( ...
[33]
[PDF] The Complement System - QuidelOrtho
C3b is first cleaved by Factor I and co-factors into iC3b and C3f. iC3b is then cleaved into C3c and C3dg, which is further cleaved into C3d.
[34]
Complement Receptor 2 Based Immunoassay Measuring Activation ...
Both C3dg and iC3b bind to complement receptor 2 (CR2), which is present on B lymphocytes and follicular dendritic cells (24) (Figure 1).
[35]
IC3b – Knowledge and References - Taylor & Francis
CR2 not only stimulates the B cells directly but also associates with CD19, another B-cell membrane protein that is known to greatly stimulate antibody ...
[36]
Covalent binding of C3b to C4b within the classical complement ...
Feb 25, 1992 · Covalent binding of C3b to a single specific site on C4b within the classical pathway C5 convertase is likely a common phenomenon in the mammalian complement ...Missing: TED domain
[37]
Structure/function of C5 convertases of complement - ScienceDirect
C5 convertases are serine proteases that cleave both C3 and C5. Alternative pathway C3/C5 convertases formed with monomeric C3b (C3b,Bb) because of their weak ...
[38]
[PDF] Complement Inhibitors Targeting C3, C4, and C5
native (C3b3bBb) pathway C5 convertases, which cleave C5 at. Arg-Leu" to generate anaphylatoxic peptide C5a (11.2 kDa) and. C5b. On a molar basis C5a is 100 ...
[39]
MEMBRANE ATTACK BY COMPLEMENT: THE ASSEMBLY AND ...
C5 convertase binds to C5 and cleaves it to generate C5a and C5b. After binding to C5b, C6 acquires the ability to interact with the lipid bilayer and form ...
[40]
a review of the complement membrane attack complex - Journals
Jun 19, 2017 · C5b initiates MAC assembly on membranes in the immediate vicinity of activation. Similar to the transition of C3 to C3b, C5 cleavage results in ...
[41]
Complement Membrane Attack Complex: New Roles, Mechanisms ...
MAC is generated through sequential assembly from the soluble complement proteins C5b, C6, C7, C8, and C9. ... MAC sequential assembly on nucleated cells using ...
[42]
Overview of Complement Activation and Regulation - PMC
The classical pathway (CP) uses C1 and is triggered by antigen–antibody immune complexes. Inactive C1 circulates as a serum molecular complex comprising six C1q ...
[43]
Complement regulation: physiology and disease relevance - PMC
This review focuses on complement regulators, the mechanisms by which complement is controlled on different biological surfaces.
[44]
https://pmc.ncbi.nlm.nih.gov/articles/PMC4543182/
[45]
https://doi.org/10.1038/nri2620
[46]
https://doi.org/10.1016/j.semnephrol.2013.08.001
[47]
Complement and its role in innate and adaptive immune responses
Dec 15, 2009 · The classical pathway is activated when C1q binds to antibody attached to antigen, activating C1r and C1s, which cleave C4 and C2. The lectin ...<|control11|><|separator|>
[48]
https://www.nature.com/articles/cr2009139
[49]
C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus
C1q deficiency is a rare immunodeficiency, which is strongly associated with the development of systemic lupus erythematosus (SLE).
[50]
Systemic Lupus Erythematosus and Deficiencies of Early ... - PubMed
Feb 24, 2016 · The deficiency of early complement proteins from the classical pathway (CP) is strongly associated with development of systemic lupus erythematous (SLE)
[51]
Hereditary angioedema: Linking complement regulation to the ...
Hereditary angioedema is caused by a deficiency in complement C1 inhibitor. · C1 inhibitor is not only a regulator of complement activity but also has a major ...
[52]
Anti-C1q antibodies: a biomarker for diagnosis and management of ...
Jun 12, 2024 · Anti-C1qAb hold promise as noninvasive markers for assessing LN activity in SLE patients. Measuring anti-C1qAb levels could aid in diagnosing and managing LN.C1q and anti-C1q antibodies · Anti-C1q and SLE · Anti-C1q in lupus nephritis
[53]
Antibodies against C1q Are a Valuable Serological Marker for ...
Anti-C1q antibodies were strongly associated with disease activity and LN in SLE patients, suggesting that it may be a reliable serological marker for ...
[54]
Classical pathway deficiencies – A short analytical review
Infections in C3 deficiency are typically caused by encapsulated bacteria due to insufficient opsonization with C3 fragments.
[55]
The complement system: A key player in the host response to ...
Aug 27, 2024 · The complement system is a key arsenal of the host defense response to pathogens and bridges both innate and adaptive immunity.
[56]
The state of complement in COVID-19 | Nature Reviews Immunology
Dec 15, 2021 · Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19.
[57]
Complement and microglia mediate early synapse loss in Alzheimer ...
Mar 31, 2016 · During development, C1q and C3 localize to synapses and mediate synapse elimination by phagocytic microglia (5–7). We hypothesized that this ...<|control11|><|separator|>
[58]
Human C1-esterase inhibitor concentrate (Berinert) - PubMed
Intravenous C1-INH concentrate was well tolerated in patients with hereditary angioedema, with no confirmed cases of viral transmission. Publication types.
[59]
Efficacy and safety of an intravenous C1-inhibitor concentrate ... - NIH
In this international registry, IV pnf-C1-INH given as LTP for HAE was safe and efficacious, with a low rate of attacks that required pnfC1-INH treatment.
[60]
Genetic Variants in C5 and Poor Response to Eculizumab
Feb 13, 2014 · Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement–mediated hemolysis associated with paroxysmal ...
[61]
Incomplete inhibition by eculizumab: mechanistic evidence for ...
Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of the complement protein C5 and shows remarkable clinical benefits ...
[62]
Measuring the 50% Haemolytic Complement (CH50) Activity of Serum
Mar 29, 2010 · The CH50 tests the functional capability of serum complement components of the classical pathway to lyse sheep red blood cells (SRBC) pre-coated ...
[63]
Biomarkers of the Complement System Activation (C3a, C5a, sC5b ...
Jul 23, 2023 · The aim of this study was the evaluation of the concentration of selected biomarkers' complement system activation (C3a, C5a, and sC5b-9 ( ...
[64]
Overview: SC5b-9 Level Terminal Complement Complex, Plasma
Useful for suggests clinical disorders or settings where the test may be helpful detecting increased complement activation.
[65]
Sustained inhibition of complement C1s with sutimlimab over 2 ...
May 29, 2023 · Sutimlimab sustains improvements in hemolysis, anemia, and quality of life over a median of 144 weeks of treatment.
[66]
C1Q-MIMIKING SCFV FRAGMENTS BINDING ANTI-C1Q ...
May 21, 2025 · The treatment with anti-idiotypic scFv antibodies has disease-progression effect on lupus symptoms in MRL/lpr murine model of SLE.
[67]
Gene Therapy for C1 Esterase Inhibitor Deficiency in a Murine ... - NIH
A single treatment with AAVrh.10hC1EI has the potential to provide long term protection from angioedema attacks in affected individuals.
[68]
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary ...
Feb 1, 2024 · NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1), with the goal of lifelong control of angioedema attacks after a single dose. Methods: ...
[69]
Complement System: An Immunotherapy Target in Colorectal Cancer
The complement system was known to be an immune surveillance system against cancer due to its activity on tumor cells via MAC accumulation-mediated cell lysis ...Abstract · Introduction to Immunotherapy... · Therapeutic Aspects of the...
[70]
CRISPR-Based Therapy for Hereditary Angioedema - PubMed
Jan 30, 2025 · NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total ...